
Sunil Verma, MD, MSEd, FRCPC, discusses evolving standards of early stage HER2-positive breast cancer.

Your AI-Trained Oncology Knowledge Connection!


Sunil Verma, MD, MSEd, FRCPC, discusses evolving standards of early stage HER2-positive breast cancer.

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses targeting HER2 in patients with early-stage breast cancer.

Sunil Verma, MD, MSEd, FRCPC, associate professor, University of Toronto, chair, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, comments on HER2 testing and the utility of Ki67.

Sunil Verma, MD, MSEd, FRCPC, University of Toronto, Breast Medical Oncology, Sunnybrook Odette Cancer Centre, discusses advances in the treatment of patients with metastatic HER2-positive breast cancer.

Published: April 2nd 2014 | Updated:

Published: May 8th 2014 | Updated:

Published: May 28th 2014 | Updated:

Published: September 5th 2014 | Updated: